The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study
Related Experiment Video
Updated: May 27, 2025
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Da Zhou1, Jiahao Song1, Guangyu Han1
1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China (Drs Zhou, Song, Han, Zhang, Ji, Meng); Advanced Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China (Drs Zhou, Song, Han, Zhang, Ji, Meng); National Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University, Beijing, China (Drs Zhou, Song, Han, Zhang, Ji, Meng).
Background:
Observational studies have suggested potential correlations between unfavorable lipid profiles and the occurrence of intracranial aneurysms (IAs), proposing that lipid-lowering therapies might curb IA progression and prevent rupture. This study aimed to explore the causal impacts of lipid-reducing strategies on the risk of IAs.
Methods:
We employed 3 genetic tools as proxies for our exposures and assessed causal effects using outcome genome-wide association study data from the FinnGen Biobank. Single nucleotide polymorphisms strongly associated with low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol, and triglycerides, located within ±100 kb of the region of target genes, were selected as instrumental variables for drug-target Mendelian randomization (MR). Additionally, gene expression and protein MR analyses were conducted to elucidate the causal effects of lipid levels from transcriptional and translational perspectives, using two-sample MR (TSMR) and summary-data-based MR (SMR).
Results:
Drug-target MR analysis revealed that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition-mediated LDL-C reduction was associated with an increased risk of IA development (odds ratio [OR] = 1.406, P = 3.28E-09). In contrast, protein MR demonstrated that higher PCSK9 expression had protective effects against IA incidence (ORTSMR = 0.896, P = 1.79E-03; ORSMR = 0.881, P = 1.78E-02). Subgroup analyses further suggested that PCSK9 might reduce the risk of IA rupture (ORTSMR = 0.893, P = 1.08E-02; ORSMR = 0.866, P = 3.39E-02).
Conclusion:
Our MR analyses indicated a potential causal relationship between higher PCSK9 expression and a reduced risk of both IA formation and rupture, highlighting the dual role of PCSK9 inhibitors in cerebrovascular disease. Hence, careful consideration is warranted when prescribing PCSK9 inhibitors, particularly in patients at risk for developing IAs.
More Related Videos
08:21Author Spotlight: A Pharmacodissection Approach to Uncover Mechanisms in Cardiovascular Disease Risk Populations
Published on: July 21, 2023
09:06Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
Published on: February 20, 2019
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...